Role of signaling lymphocytic activation molecule family of receptors in the pathogenesis of rheumatoid arthritis: insights and application.
biomarker
immunity
inflammation
rheumatoid arthritis
the signaling lymphocytic activation molecule family of receptors
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
10
2023
accepted:
23
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint damage. The signaling lymphocytic activation molecule (SLAMF) family of receptors are expressed on various hematopoietic and non-hematopoietic cells and can regulate both immune cell activation and cytokine production. Altered expression of certain SLAMF receptors contributes to aberrant immune responses in RA. In RA, SLAMF1 is upregulated on T cells and may promote inflammation by participating in immune cell-mediated responses. SLAMF2 and SLAMF4 are involved in regulating monocyte tumor necrosis factor production and promoting inflammation. SLAMF7 activates multiple inflammatory pathways in macrophages to drive inflammatory gene expression. SLAMF8 inhibition can reduce inflammation in RA by blocking ERK/MMPs signaling. Of note, there are differences in SLAMF receptor (SFR) expression between normal and arthritic joint tissues, suggesting a role as potential diagnostic biomarkers. This review summarizes recent advances on the roles of SLAMF receptors 1, 2, 4, 7, and 8 in RA pathogenesis. However, further research is needed to elucidate the mechanisms of SLAMF regulation of immune cells in RA. Understanding interactions between SLAMF receptors and immune cells will help identify selective strategies for targeting SLAMF signaling without compromising normal immunity. Overall, the SLAMF gene family holds promise as a target for precision medicine in RA, but additional investigation of the underlying immunological mechanisms is needed. Targeting SLAMF receptors presents opportunities for new diagnostic and therapeutic approaches to dampen damaging immune-mediated inflammation in RA.
Identifiants
pubmed: 38027031
doi: 10.3389/fphar.2023.1306584
pii: 1306584
pmc: PMC10657885
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1306584Informations de copyright
Copyright © 2023 Zheng, Zhao, Zhou, Wei, Jiang, Xu, Chang, Shan, Xu, Shi, Schrodi, Guo and He.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunogenetics. 1996;43(1-2):13-9
pubmed: 8537117
N Engl J Med. 2004 Jun 17;350(25):2572-81
pubmed: 15201414
Clin Immunol. 2016 Mar;164:10-20
pubmed: 26794910
Nature. 2017 Apr 27;544(7651):493-497
pubmed: 28424516
PLoS One. 2019 Jun 14;14(6):e0218109
pubmed: 31199820
Blood. 2006 Apr 1;107(7):2821-9
pubmed: 16317102
J Biol Chem. 2012 Nov 2;287(45):38168-77
pubmed: 22989874
Immunol Rev. 2010 Jan;233(1):233-55
pubmed: 20193003
J Exp Med. 1989 Mar 1;169(3):1087-99
pubmed: 2466936
Front Immunol. 2016 Jan 20;7:4
pubmed: 26834746
Nat Genet. 2015 Sep;47(9):1085-90
pubmed: 26258845
Eur J Immunol. 2010 Feb;40(2):378-87
pubmed: 19904767
J Immunol. 1997 Sep 15;159(6):2986-93
pubmed: 9300723
Exp Dermatol. 2018 Jun;27(6):641-646
pubmed: 29498772
Front Immunol. 2021 Apr 01;12:626193
pubmed: 33868244
J Immunol. 2007 Oct 1;179(7):4672-8
pubmed: 17878365
Nat Genet. 2008 Oct;40(10):1224-9
pubmed: 18794858
J Immunol. 2004 Jul 1;173(1):174-80
pubmed: 15210772
Int J Mol Sci. 2022 Jan 14;23(2):
pubmed: 35055087
Nature. 1995 Jul 20;376(6537):260-3
pubmed: 7617038
Ann Rheum Dis. 2019 Nov;78(11):1463-1471
pubmed: 31511227
Eur J Immunol. 2004 Jun;34(6):1663-72
pubmed: 15162436
J Immunol. 2001 May 1;166(9):5675-80
pubmed: 11313408
N Engl J Med. 2001 Mar 1;344(9):655-64
pubmed: 11228281
Vasc Cell. 2013 Jun 01;5(1):11
pubmed: 23725043
Blood. 2005 Jun 1;105(11):4383-9
pubmed: 15677558
Arthritis Res Ther. 2022 Sep 6;24(1):215
pubmed: 36068607
Scand J Rheumatol. 2006 Jul-Aug;35(4):268-72
pubmed: 16882589
J Exp Med. 2004 May 3;199(9):1255-64
pubmed: 15123745
Exp Hematol. 2003 Sep;31(9):798-805
pubmed: 12962726
Ann Rheum Dis. 2014 Jul;73(7):1316-22
pubmed: 24550173
Nat Med. 2005 Mar;11(3):340-5
pubmed: 15711562
Front Immunol. 2023 May 11;14:1174138
pubmed: 37251372
Front Biosci (Landmark Ed). 2022 Sep 28;27(9):267
pubmed: 36224010
CNS Neurosci Ther. 2019 Mar;25(3):333-342
pubmed: 30105842
Sci Transl Med. 2011 Sep 21;3(101):101ra92
pubmed: 21937757
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10583-8
pubmed: 17563375
J Immunol. 2005 May 15;174(10):5931-5
pubmed: 15879084
Blood. 2001 Jun 1;97(11):3513-20
pubmed: 11369645
Semin Immunopathol. 2010 Jun;32(2):157-71
pubmed: 20146065
PLoS One. 2017 Oct 11;12(10):e0186073
pubmed: 29020082
Front Immunol. 2015 Apr 14;6:158
pubmed: 25926831
PLoS Genet. 2013 Mar;9(3):e1003394
pubmed: 23555300
Nature. 2017 Feb 1;542(7639):110-114
pubmed: 28150777
Adv Immunol. 2008;97:177-250
pubmed: 18501771
J Cell Sci. 2018 Jun 5;131(11):
pubmed: 29871956
Nature. 2014 Feb 20;506(7488):376-81
pubmed: 24390342
Front Immunol. 2022 Mar 24;13:838884
pubmed: 35401568
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
Sci Immunol. 2022 Feb 11;7(68):eabf2846
pubmed: 35148199
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
J Immunol. 2014 May 1;192(9):4436-42
pubmed: 24670806
Blood. 2005 Nov 1;106(9):3028-34
pubmed: 16037392
Br J Haematol. 2012 Jun;157(6):687-701
pubmed: 22533610
Front Immunol. 2017 Oct 18;8:1341
pubmed: 29093715
Immunogenetics. 2002 Feb;53(10-11):843-50
pubmed: 11862385
J Immunol. 2001 Oct 1;167(7):3668-76
pubmed: 11564780
Immunity. 2006 Oct;25(4):559-70
pubmed: 17045824
Clin Immunol. 2019 Jul;204:43-49
pubmed: 30522694
Nat Rev Immunol. 2006 Jan;6(1):56-66
pubmed: 16493427
Arthritis Res Ther. 2013;15(6):R207
pubmed: 24299175
Immunity. 2016 Aug 16;45(2):292-304
pubmed: 27521267
Nat Cell Biol. 2003 Feb;5(2):155-60
pubmed: 12545174
Drug News Perspect. 2008 Jun;21(5):245-50
pubmed: 18596988
J Immunol. 1999 Dec 1;163(11):5860-70
pubmed: 10570270
PLoS One. 2012;7(8):e42507
pubmed: 22880008
Nan Fang Yi Ke Da Xue Xue Bao. 2022 May 20;42(5):733-739
pubmed: 35673918
Arthritis Res Ther. 2006;8(4):R88
pubmed: 16684368
Tissue Antigens. 1990 May;35(5):203-5
pubmed: 1976277
Immunotargets Ther. 2020 Mar 09;9:43-56
pubmed: 32211348
Autoimmunity. 2022 Aug;55(5):294-300
pubmed: 35506438
Int Immunopharmacol. 2022 Jun;107:108644
pubmed: 35259711
Gastroenterology. 2015 May;148(5):991-1001.e4
pubmed: 25678452
J Immunol. 2006 Sep 1;177(5):3170-7
pubmed: 16920955
Cancer Med. 2019 Apr;8(4):1576-1583
pubmed: 30873760
Front Immunol. 2022 Dec 06;13:1054451
pubmed: 36561742
Front Immunol. 2022 Aug 30;13:961129
pubmed: 36110846
Clin Transl Immunology. 2021 Oct 26;10(10):e1347
pubmed: 34729183
Ann Rheum Dis. 2012 Jun;71(6):1004-11
pubmed: 22258493
Adv Clin Exp Med. 2019 May;28(5):665-670
pubmed: 30740946
Sci Rep. 2020 Feb 13;10(1):2505
pubmed: 32054954
Adv Immunol. 2019;143:75-98
pubmed: 31607368
Blood. 2002 Oct 15;100(8):2899-907
pubmed: 12351401
Monoclon Antib Immunodiagn Immunother. 2014 Aug;33(4):209-14
pubmed: 25170999
Clin Rheumatol. 2019 Jan;38(1):181-187
pubmed: 28940139
Immunogenetics. 2000 Sep;51(11):987-92
pubmed: 11003394
J Immunol. 2012 Feb 1;188(3):1206-12
pubmed: 22184727
Clin Immunol. 2019 Jul;204:23-30
pubmed: 30448442
Front Immunol. 2022 Jul 08;13:907733
pubmed: 35874704
Dis Markers. 2016;2016:4895050
pubmed: 27478294
Front Immunol. 2022 Mar 03;13:863703
pubmed: 35309322
Autoimmun Rev. 2018 Jul;17(7):674-682
pubmed: 29729453
J Exp Med. 1997 Mar 17;185(6):993-1004
pubmed: 9091591
J Orthop Surg Res. 2022 Jan 11;17(1):13
pubmed: 35016729
Ann Rheum Dis. 2020 Nov;79(11):1438-1445
pubmed: 32723749